Marta Kończak

Ms. Marta Kończak

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2026 in Acta Poloniae Pharmaceutica - Drug Research
Verified
Journal Article
Open access
MKMarta Kończak
Marta Kończak
WKWitold Kowal
Witold Kowal
PRPiotr Ratajczak
Piotr Ratajczak
APAnna Paczkowska
Anna Paczkowska
DKDorota Kopciuch
Dorota Kopciuch
TZTomasz Zaprutko
Tomasz Zaprutko
Advertising of medicinal products during children’s television programming is strictly regulated in Poland (Article 53, paragraph 3 of the Pharmaceutical Law) and other European Union member states, where targeting pharmaceutical messages at minors is prohibited. This study aimed to verify the presence, frequency, and duration of pharmaceutical advertisements in children's programming, comparing Poland with Spain, France, Italy, Germany, Denmark, and Sweden. The material consisted of publicly available broadcasts from selected children's channels: in Poland (July-August 2024), in other countries (November 2024), and in all locations again (December 2024). During each of these periods, observers analysed selected, randomly chosen 60-minute broadcast segments aired between 7:00 AM and 8:00 PM, recording total advertising time and pharmaceutical spot duration. Advertised products were classified into therapeutic groups (e.g., analgesics, vitamins, cold remedies). Pharmaceutical advertising directed at children was found only in Poland and Spain. In Poland, such ads represented 22.3% of total advertising time in summer 2024 (2 min 11 s of 9 min 46 s) and 14.6% in December 2024 (38 s of 4 min 22 s). In Spain, a single instance occurred in November 2024, representing 13.7% (20s of 2 min 25s) of total advertising time. No pharmaceutical advertisements targeting children were detected in France, Italy, Germany, Denmark, or Sweden. Pharmaceutical advertising during children’s programming persists in Poland despite legal restrictions, suggesting insufficient enforcement. In contrast, the absence of such content in other EU countries indicates effective regulation and oversight that protect minors from exposure to pharmaceutical marketing.

22 July 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
MKMarta Kończak
Marta Kończak
Izabela Anna BolesławskaIzabela Anna Bolesławska
Izabela Anna Bolesławska
PJPawel Jagielski
Pawel Jagielski
DKDominika Kusyk
Dominika Kusyk
SDSławomira Drzymała-Czyż
Sławomira Drzymała-Czyż
Sarcopenia is an age-related progressive decline in skeletal muscle mass, strength, and physical performance that increases the risk of falls, disability, and reduced quality of life among older adults. Its pathogenesis is multifactorial and involves chronic low-grade inflammation, hormonal disturbances, insulin resistance, and mitochondrial dysfunction, leading to an imbalance between muscle protein synthesis and degradation. The aim of this study was to summarise current knowledge regarding the mechanisms underlying sarcopenia, contemporary diagnostic methods, and the effectiveness of modern nutritional and exercise-based strategies, with particular emphasis on technologies supporting patient monitoring. This study is a structured narrative review conducted across PubMed, Scopus, and Web of Science databases, with the literature search completed on 1 March 2026. Separate searches were performed for thematic sections, including pathophysiology, diagnosis, physical activity, nutritional interventions, plant-derived compounds, and digital health technologies. While the core search focused on publications from 2023–2025, specific time-bound deviations were applied: the search for plant-derived compounds was extended back to 2020, and combined interventions were searched up to March 2026 to ensure the inclusion of the most recent evidence. The review included 53 peer-reviewed primary studies (RCTs and observational) and secondary literature (reviews and meta-analyses) involving individuals aged ≥60 years. The most robust evidence supports multicomponent interventions, particularly the synergy between resistance training and adequate protein intake (1.2–1.5 g/kg/day), often supplemented with leucine, vitamin D, omega-3 fatty acids, and creatine. Such strategies effectively counteract anabolic resistance by combining mechanical loading with the stimulation of the mTORC1 signalling pathway, leading to significant improvements in muscle mass, strength, and physical function. While isolated protein or micronutrient supplementation shows limited effectiveness in the absence of exercise, their role as supportive elements in multimodal strategies is well-documented. Furthermore, emerging digital health technologies—including wearable sensors and telerehabilitation—are proving essential for clinical practice, enabling precise, continuous monitoring of physical activity and gait parameters under free-living conditions, which enhances both patient adherence and long-term therapeutic outcomes.